Evidence map›Paper›PMID 42050554›Full record

ArticleJournal of nanobiotechnology2026

Biomimetic β-lapachone and hemin nanoassembly for intracellular oxidation cascade amplified ferroptosis in hepatocellular carcinoma therapy.

Jiyue Wang, Yongyi Liang, Wenxiang Qi, Wenjun Li, Donglin He, Lei Ding, Lingjie Wu, Ming Wu, Yupeng Sun, Yongyi Zeng and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jiyue Wang *College of Life Science, Fujian Agriculture and Forestry University, Fuzhou, 350002, Fujian, P. R. China.
Yongyi Liang *College of Life Science, Fujian Agriculture and Forestry University, Fuzhou, 350002, Fujian, P. R. China.
Wenxiang QiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China.
Wenjun LiThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China.
Donglin HeCollege of Life Science, Fujian Agriculture and Forestry University, Fuzhou, 350002, Fujian, P. R. China.
Lei DingThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China.
Lingjie WuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China.
Ming WuThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China.
Yupeng SunThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China.
Yongyi ZengThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China.
Xiaolong LiuCollege of Life Science, Fujian Agriculture and Forestry University, Fuzhou, 350002, Fujian, P. R. China. xiaoloong.liu@gmail.com.
Yao HuangThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China. huangyao8055@163.com.
Jingfeng LiuCollege of Life Science, Fujian Agriculture and Forestry University, Fuzhou, 350002, Fujian, P. R. China. drjingfeng@126.com.
Xiaolong ZhangThe United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350007, P. R. China. xiaolongdo@gmail.com.

Funding

Joint Funds for the Innovation of Science and Technology of Fujian Province 2025Y9482 and 2023Y9268Natural Science Foundation of Fujian Province of China 2024J011224 and 2023J05093the National Natural Science Foundation of China 22274023
6 · The paper itself

Abstract

Ferroptosis represents one of important no-apoptotic programmed cell death with over accumulation of iron- and reactive oxygen species (ROS). While its key role and trials for cancer therapy, achieving precise and potent induction ferroptosis in cancer cells with massive amplification of cellular lipid peroxidation and iron overloading, remains a significant hurdle. Herein, we developed a biomimetic red blood cell membranes (RBCM) camouflaged β-lapachone (Lap) and hemin nanoassembly (LHNPs@RBCM) as ferroptosis inducer for hepatocellular carcinoma (HCC) therapy. The RBCM endowed the nanoassembly with prolonged systemic circulation and improved tumor accumulation. After endocytosis of LHNPs@RBCM by cancer cells, the cancer-specific overexpressed NAD(P)H: quinone oxidoreductase (NQO1) converted the released Lap to ROS (e.g. O

Indexed as

Biomimetic MaterialsCarcinoma, HepatocellularFerroptosisHeminLiver NeoplasmsNaphthoquinonesAnimalsCell Line, TumorHumansHydrogen PeroxideIronLipid PeroxidationMiceNAD(P)H Dehydrogenase (Quinone)Oxidation-ReductionReactive Oxygen Speciesbeta-lapachoneHeminHydrogen PeroxideIronNAD(P)H Dehydrogenase (Quinone)NaphthoquinonesNQO1 protein, humanReactive Oxygen SpeciesCarrier-freeHepatocellular CarcinomaHydroxyl radicalLipid peroxidesReactive oxygen species

Identifiers

PMID42050554
PMCPMC13273984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.